Biotech’s issues about RFK Jr.; Novartis blockbuster failed trial

And so, one other working week will quickly draw to a detailed. Already, you say? Effectively, there’s a vacation arising on this aspect of the pond. So we’re fortunately daydreaming about weekend plans. Our agenda is unsure. We do plan, nevertheless, to hold with all of our quick folks, nosh on some favourite meals, and, sure, maintain yet one more itemizing occasion. This time round, the rotation will probably embody this, this, this, this and this. And what about you? There could also be no higher time to benefit from the nice outdoor, a perennial aspiration of ours. In any case, mountaineering trails, boardwalks, and nation roads are beckoning. You might additionally take a second to twist up with guide or look in on somebody particular. Otherwise you would possibly wish to merely plan the remainder of your life. Effectively, no matter you do, have a grand time. However be secure. Take pleasure in, and see you on Monday. …

A memo that purports to summarize a gathering held by members of a number one biotech commerce group suggests deep concern about well being secretary Robert F. Kennedy Jr.’s stance on vaccines, and describes him as a “direct menace to public well being,” STAT writes. The four-page doc purportedly particulars subjects of dialog at an April 3 assembly of a vaccine coverage committee of the commerce group BIO, wherein attendees mentioned anxieties about Kennedy’s positions on vaccines and techniques to have interaction with extra conservative influencers. The doc additionally consists of an obvious quote from somebody in attendance: “it’s time to go to The Hill and foyer that it’s time for RFK Jr to go.” BIO mentioned the memo was not produced by the group and doesn’t mirror its plans. “We now have by no means seen or heard of this doc and it definitely doesn’t precisely signify the spirit, technique, or mission of BIO’s work,” spokesperson Scott Frotman mentioned in an announcement.

Novartis’s drug Cosentyx failed in a late-stage research of sufferers affected by irritation of their blood vessels, a blow to its efforts to search out new makes use of for the blockbuster medication, Bloomberg Information tells us. The remedy, already one among Novartis’s prime sellers, didn’t exhibit statistically important enchancment in grownup sufferers affected by large cell arteritis, an ailment that may trigger lack of imaginative and prescient and life-threatening aneurysms. The drug was in contrast with placebo, with all trial contributors additionally getting a steroid. Cosentyx is already used for treating illnesses together with psoriasis and the drug is anticipated to generate about $7 billion in gross sales this yr, in accordance with information compiled by Bloomberg. Novartis chief govt officer Vas Narasimhan not too long ago mentioned that if Cosentyx proved profitable in treating large cell arteritis, it might herald one other $500 million in income yearly. The corporate had listed the trial as one among its largest pipeline occasions in 2025. It mentioned it plans a full analysis of the trial information and can share extra outcomes at a later date.

STAT+ Unique Story

STAT+